2016 American Transplant Congress
Elderly Kidney Transplant Recipients Need Optimized Immunosuppression According to Comorbidity and Infection.
Backgrounds: The numbers of elderly kidney transplantation is increasing, but there are limited studies about the use of immunosuppressant in this group. We investigated the…2016 American Transplant Congress
Rare Presentation of PTLD as Parotitis.
Medicine, MUSC, Charleston, SC.
28y/o AAF w/ hx of CAH, HTN, and ESRD, was on HD for 3 yrs. Pt was EBV seronegative prior to transplant (tx). She received…2016 American Transplant Congress
Kinetics of Cytomegalovirus Load in Kidney Transplant Recipients Receiving Everolimus or Mycophenolate Sodium and No Pharmacological Prophylaxis.
Hospital do Rim, São Paulo, Brazil.
The purpose of this analysis is to investigate the kinetics of cytomegalovirus (CMV) viral load in kidney transplant recipients receiving tacrolimus (TAC) plus everolimus (EVR)…2016 American Transplant Congress
Belatacept Conversion in Adult Kidney Transplant Recipients for Cause: A Single Center Observational Cohort.
Background: Calcineurin inhibition (CNI) is the single most effective strategy to prevent allograft rejection however tolerability is limited by toxicity. To date, alternate strategies have…2016 American Transplant Congress
Evaluation of Patient-Reported Nonadherence with Tacrolimus Level Variability in Renal Transplant Recipients.
Medication nonadherence (NA) continues to be a major cause of graft loss post-transplant. Several methods for prospective adherence monitoring have been described including patient interview…2016 American Transplant Congress
Predictive Model for Medication Errors in a Chronic Kidney Transplant Clinic.
Medication errors are associated with increased incidence of infection, rejection, and graft loss in kidney transplant recipients. This study aims to create a model to…2016 American Transplant Congress
Impact of Low Dose Tacrolimus with Everolimus Regimen on Renal Pathology and T-Regulatory Cells in Kidney Transplant.
Calcineurin inhibitors (CNI) serve as the cornerstone of immunosuppression (IS) after kidney transplant. However chronic CNI nephrotoxicity has been implicated in allograft dysfunction. We hypothesize…2016 American Transplant Congress
Increasing Tacrolimus Time-in-Therapeutic Range Is Associated with Less Cellular Rejection in Lung Transplant Recipients.
University of Pittsburgh, Pittsburgh, PA.
Purpose: To describe the effect of tacrolimus (FK) time-in-therapeutic range (TTR) on incidence of cellular rejection (ACR) within the first year after lung transplantation (LT).Methods:…2016 American Transplant Congress
Comparison of Clinical Outcomes of Belatacept- and Tacrolimus-Based Immunosuppression in Renal Transplant Recipients.
To examine the utilization and clinical outcomes of belatacept in the real clinical setting, a retrospective cohort study was conducted using SRTR data that compared…2016 American Transplant Congress
Comparison of Efficacy and Safety of a 4-Month Post-Renal Transplant Dose Reduction of Tacrolimus.
Introduction. The aim of the study was to determine the efficacy and safety balance of 2 different doses of tacrolimus extended-release (TacER) in kidney transplant…
- « Previous Page
- 1
- …
- 108
- 109
- 110
- 111
- 112
- …
- 138
- Next Page »